Skip to main content
. 2015 Nov 1;25(11):1209–1216. doi: 10.1089/thy.2015.0297

FIG. 4.

FIG. 4.

Thyroid cancer–specific survival and recurrence stratified by ETE or DM. (A) Thyroid cancer–specific survival with new diagnosis of FTC based on the presence of ETE or DM. Median survival with ETE or DM was 11 years. (B) Recurrence for patients with new diagnosis of FTC based on the presence of ETE or DM. Cox hazard ratio 35.4 ± 29.7, p < 0.01. Median time to recurrence was two years if there was ETE. Patients with DM were excluded from the recurrence analysis—considered persistent disease. ETE, extrathyroidal extension; DM, distant metastasis.